Angela Dominy Radkowski was named Chief Operating Officer of Tharimmune, Inc., effective February 5, 2026. As of November 14, 2026, Tharimmune, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 6, 2026, naming 1 appointment (Form 8-K, February 6, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Tharimmune, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Tharimmune, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Tharimmune, Inc. files it.
Also on the record for Tharimmune, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 4.74% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G/A, by Murtaza S. Akbar | 9.99% of the class | 5%+ stakes | Source |
| April 15, 2026 | Form D, private offering | $1.74M sold | Form D page | Source |
| April 15, 2026 | Form D, private offering | $1.23M sold | Form D page | Source |
| February 6, 2026 | Stake report, Schedule 13G, by Broadridge Financial Solutions, Inc. | 9.99% of the class | 5%+ stakes | Source |
| February 3, 2026 | Stake report, Schedule 13G, by ARK Investment Management LLC | 8.92% of the class | 5%+ stakes | Source |
| February 2, 2026 | Stake report, Schedule 13G, by LCV Fund III, L.P. | 9.99% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2.2% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 9.8% of the class | 5%+ stakes | Source |
| July 7, 2025 | Form D, private offering | $2.50M sold | Form D page | Source |
| December 17, 2024 | Form D, private offering | $2.02M sold | Form D page | Source |
Selling to them or working with them? See who runs Tharimmune, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tharimmune, Inc. and the records around it.
The people at Tharimmune, Inc.
- Gary Stetz, Sireesh Appajosyula and Vincent LoPriore are also named on 6 other Form D filings: Hepion Pharmaceuticals, Inc. (Aug 2026)
Tharimmune, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Tharimmune, Inc.
Get an email when Tharimmune, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tharimmune, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tharimmune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tharimmune, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-06 | In | Chief Operating Officer | 2026-02-05 | 8-K, 2026-02-06 |
Who leads Tharimmune, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Angela Dominy Radkowski, appointed, effective 2026-02-05 (filed 2026-02-06).
New leaders reset buying decisions — get the Full Report on Tharimmune, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Tharimmune, Inc. (free up to 3)
Find people with the same kind of experience as the Chief Operating Officer at Tharimmune, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Tharimmune, Inc.Every change, in the filing's words
Appointed: Angela Dominy Radkowski, Chief Operating Officer, effective 2026-02-05
On February 5, 2026, the Board of Directors (the " Board ") of Tharimmune, Inc. (the " Company ") appointed Angela Dominy Radkowski, age 37, as Chief Operating Officer of the Company, effective February 5, 2026 (the " Effective Date ").
- Prior to her appointment, Ms. Radkowski served as Operations Strategy Lead and Chief of Staff to the Chief Operating Officer at DRW Holdings LLC from February 2022 to January 2026, advising senior leadership, coordinating cross-functional communication, and managing high-priority, enterprise-level initiatives.
- Ms. Radkowski previously held positions within Citadel LLC's Treasury and Engineering organizations, where she was responsible for coordinating enterprise deliverables involving optimization, data engineering, and technology upgrades.
- Ms. Radkowski holds a Bachelor of Science in Business Administration with a major in Finance from The Ohio State University, Max M. Fisher College of Business.
- Ms. Radkowski will also be eligible to receive grants of time-based and/or performance-based equity awards, in a form and amount determined by the Board in its sole and absolute discretion, subject to Board approval, vesting conditions established by the Board (or its compensation committee) and other conditions.
- The agreement contains customary confidentiality, non-compete, non-solicitation, and intellectual property provisions.
- The COO Employment Agreement provides that Ms. Radkowski's employment is at will and may be terminated by either party at any time, with or without cause or notice.
Tharimmune, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Tharimmune, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
